| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | GSL; GLB2; NGBE; PPCA; PPGB |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CTSA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CTSA(组织蛋白酶A)抗体的模拟参考文献示例(请注意，这些为虚构文献，仅用于示例用途)：
---
1. **标题**：*Development of a Monoclonal Antibody Against Human Cathepsin A for Lysosomal Disease Diagnostics*
**作者**：Smith J, et al.
**摘要**：本研究开发了一种高特异性的单克隆抗体，用于检测人类组织蛋白酶A(CTSA)在溶酶体贮积症患者中的表达水平。通过免疫印迹和免疫组化验证，该抗体在区分CTSA缺陷型(如半乳糖唾液酸贮积症)与健康对照组中表现出高敏感性和特异性。
2. **标题**：*CTSA as a Biomarker in Colorectal Cancer: Immunohistochemical Analysis Using Novel Polyclonal Antibodies*
**作者**：Lee H, et al.
**摘要**：研究利用新型多克隆抗体分析CTSA在结直肠癌组织中的表达，发现CTSA在肿瘤微环境中的高表达与患者预后不良相关，提示其可能作为潜在治疗靶点或预后标志物。
3. **标题**：*Targeting CTSA in Neurodegenerative Disorders: Antibody-Based Inhibition of Enzymatic Activity*
**作者**：Garcia R, et al.
**摘要**：文章报道了一种能特异性抑制CTSA酶活性的功能性抗体，并在阿尔茨海默病模型中验证其减少β-淀粉样蛋白沉积的效果，为神经退行性疾病治疗提供了新策略。
4. **标题**：*Comparative Study of CTSA Antibody Performance in Western Blot vs. ELISA Assays*
**作者**：Wang Y, et al.
**摘要**：比较了市售CTSA抗体在Western blot和ELISA中的性能差异，提出针对不同实验场景的抗体选择建议，强调表位特异性对抗体功能分析的关键影响。
---
**提示**：实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词如“Cathepsin A antibody”或“CTSA inhibitor”)，并优先选择近5年发表的高被引论文以获取最新进展。
Cathepsin A (CTSA), also known as lysosomal protective protein or carboxypeptidase A, is a multifunctional serine protease belonging to the peptidase S10 family. It plays a critical role in lysosomal protein degradation by stabilizing and activating two key lysosomal enzymes: β-galactosidase (GLB1) and neuraminidase-1 (NEU1). CTSA forms a protective multienzyme complex with these proteins, preventing their premature degradation and ensuring proper lysosomal function. Dysregulation of CTSA is linked to lysosomal storage disorders, particularly galactosialidosis, an inherited condition caused by CTSA gene mutations that lead to systemic accumulation of undegraded substrates.
CTSA also participates in extracellular processes, including peptide hormone processing, blood pressure regulation via inactivation of bradykinin, and extracellular matrix remodeling. Its dual intra- and extracellular roles connect it to various pathologies beyond lysosomal disorders, including cancer metastasis, cardiovascular diseases, and neurodegeneration.
CTSA antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They enable detection in tissue samples, cell lysates, and biological fluids through techniques like Western blot, immunohistochemistry, and ELISA. Therapeutic interest in CTSA inhibitors has emerged, particularly for cancer treatment, given its role in tumor invasion and angiogenesis. Research continues to explore CTSA's complex biology and its potential as a diagnostic marker or therapeutic target.
×
